Lactobacillus Plantarum

• Gut microbiome balance
• Immune system modulation
• Intestinal barrier enhancement
• Pathogen inhibition

• Irritable Bowel Syndrome (IBS) symptom reduction
• Inflammatory Bowel Disease support
• Potential cardiovascular health benefits
• Antioxidant activity
• Potential mental health benefits
• Possible metabolic health support
• Antimicrobial properties against pathogens
• Potential for reducing antibiotic side effects

Lactobacillus plantarum exerts its beneficial effects through multiple sophisticated mechanisms that contribute to gut health, immune modulation, and protection against pathogens. One of its most distinctive features is its exceptional environmental adaptability, allowing it to survive and thrive in diverse conditions including the harsh environment of the gastrointestinal tract. L. plantarum produces a wide range of antimicrobial compounds, including multiple bacteriocins (such as plantaricin), organic acids (primarily lactic and acetic acids), and hydrogen peroxide.

These antimicrobial substances collectively inhibit the growth of pathogenic bacteria, fungi, and viruses through multiple mechanisms including disruption of cell membranes, alteration of intracellular pH, and interference with essential metabolic processes. This broad antimicrobial activity helps L. plantarum to compete effectively against pathogens in the gut environment and contributes to maintaining a balanced microbiota. A particularly important aspect of L.

plantarum’s activity is its ability to strengthen the intestinal epithelial barrier. It enhances the expression and assembly of tight junction proteins between epithelial cells, reducing intestinal permeability and preventing the translocation of pathogens and toxins across the intestinal wall. This ‘leaky gut’ prevention is crucial for reducing systemic inflammation and endotoxemia. L.

plantarum has significant immunomodulatory effects, interacting with the gut-associated lymphoid tissue (GALT) to influence both innate and adaptive immunity. It stimulates dendritic cells and macrophages, enhances natural killer cell activity, and modulates T cell responses. Importantly, L. plantarum promotes a balanced immune response by inducing regulatory T cells and anti-inflammatory cytokines (such as IL-10) while reducing pro-inflammatory cytokines (such as TNF-α and IL-6) when inflammation is excessive.

This helps maintain immune homeostasis and may contribute to its benefits in inflammatory conditions. L. plantarum is particularly effective at adhering to intestinal mucosa, which allows it to form a protective biofilm that prevents pathogen attachment and colonization. This adhesion ability varies between strains, with some strains showing particularly strong adhesion properties due to specific surface proteins and exopolysaccharides.

In the context of Irritable Bowel Syndrome (IBS), L. plantarum (particularly the LP299V strain) has been shown to reduce visceral hypersensitivity and normalize bowel habits. It achieves this through multiple mechanisms including modulation of gut motility, reduction of intestinal gas production, and normalization of the gut-brain axis signaling that influences pain perception. L.

plantarum has notable antioxidant properties, producing enzymes such as superoxide dismutase and glutathione peroxidase that neutralize reactive oxygen species. This antioxidant activity may contribute to its anti-inflammatory effects and potential benefits for cardiovascular health. For cardiovascular health, certain strains of L. plantarum have demonstrated cholesterol-lowering effects through bile salt hydrolase activity, which deconjugates bile acids and leads to increased cholesterol excretion.

Some strains can also directly assimilate cholesterol or convert it to coprostanol, which is poorly absorbed. L. plantarum contributes to the metabolism of dietary components, including the breakdown of complex carbohydrates and the production of beneficial metabolites such as short-chain fatty acids (SCFAs). These SCFAs, particularly butyrate, serve as an energy source for colonic epithelial cells, have anti-inflammatory properties, and help maintain gut barrier integrity.

L. plantarum modulates the gut-brain axis through multiple pathways, including the production of neuroactive compounds, the modulation of the vagus nerve signaling, and the reduction of systemic inflammation. This may explain its observed effects on stress, anxiety, and mood in some studies. Strain-specific effects are particularly important for L.

plantarum. Different strains have been shown to have distinct effects and mechanisms of action. For example, L. plantarum 299v has shown particular efficacy for IBS, while L.

plantarum WCFS1 has demonstrated strong immunomodulatory properties. The strain L. plantarum LP01 has shown benefits for allergic conditions through specific immune modulation pathways.

The optimal dosage of Lactobacillus plantarum varies depending on the specific condition being addressed, the strain used, and individual factors. Generally, dosages range from 1 billion to 10 billion colony-forming units (CFU) per day for general health maintenance, while therapeutic dosages for specific conditions may range from 10 billion to 20 billion CFU daily. It’s important to note that efficacy is not solely determined by CFU count but also by strain specificity, viability at the site of action, and the particular health condition being addressed. Different strains of L.

plantarum (such as LP299v, LP01, WCFS1, LP-115) have been studied at different dosages for various conditions.

Lactobacillus plantarum is not ‘absorbed’ in the traditional sense of dietary supplements. Instead, its bioavailability refers to the percentage of live bacteria that survive the harsh conditions of the gastrointestinal tract to reach their site of action. L. plantarum has relatively good survival rates compared to many other probiotic strains due to its natural acid and bile resistance.

Studies suggest that approximately 20-40% of orally administered L. plantarum may survive passage through the stomach and upper intestine, though this varies widely depending on formulation, strain characteristics, and individual factors such as gastric acidity and transit time. L. plantarum has demonstrated superior acid and bile resistance compared to many other probiotic strains, which contributes to its efficacy.

This is particularly true for certain strains like L. plantarum 299v, which has shown excellent survival through the GI tract in human studies. Once it reaches the intestines, L. plantarum can temporarily colonize the gut mucosa, with detectable levels persisting for 1-3 weeks after discontinuation in many individuals.

Some strains of L. plantarum have shown particularly good adhesion to intestinal epithelial cells, which enhances their residence time and functional effects in the gut.

Enteric coating: Protects probiotics from stomach acid, increasing survival rates by 30-60%, Microencapsulation: Shields bacteria from environmental stressors, potentially improving viability by 40-70%, Delayed-release capsules: Designed to release probiotics in the intestines rather than the stomach, Buffered formulations: Include compounds that neutralize stomach acid around the bacteria, Prebiotic inclusion (synbiotics): Provides nutrients that support probiotic growth and colonization, particularly fructooligosaccharides (FOS), inulin, and specific oligosaccharides that L. plantarum can utilize, Higher CFU counts: Compensates for die-off during transit, though quality and strain characteristics are more important than quantity alone, Refrigerated storage: Maintains viability before consumption, Consumption with meals: Food can buffer stomach acid and improve survival, Acid-resistant strains: Selection of naturally acid-resistant strains of L. plantarum, Freeze-dried preparations: Maintain stability until hydration in the digestive tract, Mucoadhesive delivery systems: Enhance adherence to the intestinal mucosa, increasing residence time

For maximum effectiveness, L. plantarum supplements are best taken with or just before meals, which helps buffer stomach acid and improve survival rates. When taken for antibiotic-associated diarrhea prevention, L. plantarum should be administered at least 2 hours before or after antibiotics to prevent direct antimicrobial effects on the probiotic.

For general digestive health, consistent daily supplementation is more important than specific timing. Morning administration may be preferable for some individuals as gastric emptying tends to be faster in the morning, potentially allowing more bacteria to reach the intestines. For inflammatory bowel conditions or irritable bowel syndrome, some practitioners recommend divided doses (morning and evening) to provide more consistent exposure throughout the day. For individuals with specific digestive symptoms, timing may be adjusted based on symptom patterns; for example, taking L.

plantarum before meals that typically trigger symptoms. When used as an adjunct to H. pylori treatment, L. plantarum should be taken at a different time than the antibiotic regimen, ideally with food.

For maximum colonization potential, consistent daily use at approximately the same time each day is recommended, as L. plantarum typically remains in the gut for only 1-3 weeks after discontinuation. Some research suggests that L. plantarum may have better survival and colonization when consumed in fermented food matrices rather than as isolated supplements, so incorporating naturally fermented foods containing L.

plantarum may be beneficial alongside supplement use.

• Temporary digestive discomfort (gas, bloating)
• Mild abdominal cramping
• Increased thirst (rare)
• Headache (rare)
• Constipation (rare)
• Increased appetite (rare)
• Taste disturbances (rare)
• Skin rash (very rare)

• Severely immunocompromised patients (e.g., those with AIDS, lymphoma, or undergoing long-term corticosteroid treatment)
• Patients with short bowel syndrome
• Individuals with central venous catheters
• Critically ill patients in intensive care units
• Premature infants (especially very low birth weight infants)
• Patients with damaged heart valves or artificial heart valves
• Known hypersensitivity to Lactobacillus species or any components of the probiotic formulation

• Antibiotics (may reduce probiotic effectiveness; separate administration by at least 2 hours)
• Immunosuppressants (theoretical increased risk of infection)
• Antifungal medications (may reduce probiotic effectiveness)
• Medications that decrease stomach acid (may increase probiotic survival but potentially affect colonization patterns)
• Anticoagulants/antiplatelet drugs (rare case reports of increased bleeding risk with certain probiotics, though not specifically with L. plantarum)

No established upper limit for L. plantarum. Doses up to 50 billion CFU daily have been used in clinical studies without significant adverse effects in healthy individuals. However, higher doses may increase the risk of side effects such as digestive discomfort without necessarily providing additional benefits.

The appropriate dose depends on the specific condition being treated and individual factors. For general health maintenance, 1-10 billion CFU daily is typically sufficient. Individuals with compromised immune systems should consult healthcare providers before using any dose of probiotics. It’s important to note that safety concerns are more related to an individual’s health status than to specific dosage thresholds.

Lactobacillus plantarum has an excellent safety profile and is one of the most widely consumed probiotics in traditional fermented foods worldwide. It has Generally Recognized as Safe (GRAS) status in the United States and Qualified Presumption of Safety (QPS) status in the European Union. However, there have been rare cases of Lactobacillus bacteremia (bacteria in the blood) in severely immunocompromised individuals or those with serious underlying health conditions. While L.

plantarum has a long history of safe use in foods and supplements, caution is advised in certain populations. Individuals with severe acute pancreatitis should avoid probiotics, as some studies have suggested potential harm in this specific condition. Those with a history of endocarditis or artificial heart valves should consult healthcare providers before use. Diabetic patients should check probiotic supplement labels for added sugars.

Individuals with milk allergies should ensure that dairy-free formulations are selected, as some L. plantarum products are cultured in dairy-based media. Patients scheduled for surgery should inform their healthcare providers about probiotic use, as some practitioners recommend discontinuation 1-2 weeks before major surgical procedures. While L.

plantarum has been consumed during pregnancy in traditional foods for centuries and is generally considered safe, pregnant women should still consult healthcare providers before starting any supplement regimen. L. plantarum has been studied for its potential to reduce the risk of necrotizing enterocolitis in preterm infants, but probiotic use in this vulnerable population should only occur under strict medical supervision.

In the United States, Lactobacillus plantarum has Generally Recognized as Safe (GRAS) status when used in traditional food applications. This GRAS status reflects its long history of safe use in fermented foods worldwide. As a dietary supplement ingredient, L. plantarum is regulated under the Dietary Supplement Health and Education Act (DSHEA) of 1994.

Under this framework, manufacturers are responsible for ensuring the safety of their products before marketing, but pre-market approval is not required. The FDA does not approve dietary supplements for safety or efficacy. Manufacturers of L. plantarum supplements may make structure/function claims (e.g., ‘supports digestive health’) but cannot make disease claims (e.g., ‘treats irritable bowel syndrome’) without going through the drug approval process.

In September 2023, the FDA issued a warning regarding the use of probiotics in hospitalized preterm infants, citing safety concerns, though this was not specific to L. plantarum alone. For food applications, L. plantarum is permitted as an ingredient in fermented foods according to the standards of identity established by the FDA.

It is also approved for use as a starter culture in various fermentation processes.

Eu: In the European Union, L. plantarum has Qualified Presumption of Safety (QPS) status, the European equivalent of GRAS. For use in foods, L. plantarum must be included on the Union list of authorized food additives. For probiotic health claims, the European Food Safety Authority (EFSA) has established strict criteria. To date, EFSA has not approved any specific health claims for L. plantarum, though it is permitted as a food ingredient and in food fermentation processes. In food supplements (the EU term for dietary supplements), L. plantarum is regulated under the Food Supplements Directive (2002/46/EC). Some member states have established national lists of permitted probiotic strains for use in food supplements. L. plantarum is widely used in traditional fermented foods throughout the EU, which have their own regulatory frameworks.

Canada: Health Canada has included L. plantarum on its Natural Health Products Ingredients Database with approved use as a source of probiotics. It is permitted in Natural Health Products (NHPs) with specific approved claims related to gut health and immune function. Some specific strains of L. plantarum have been approved for health claims related to digestive health. L. plantarum is also permitted as a food ingredient in products like fermented vegetables and dairy products. For probiotic products making health claims, pre-market approval is required through the Natural and Non-prescription Health Products Directorate (NNHPD).

Australia: In Australia, L. plantarum is regulated by the Therapeutic Goods Administration (TGA) when used in complementary medicines (similar to dietary supplements). It is listed in the Therapeutic Goods (Permissible Ingredients) Determination and can be used in listed medicines. For food applications, Food Standards Australia New Zealand (FSANZ) permits L. plantarum as a food ingredient and in food fermentation processes. Health claims are regulated under the Australia New Zealand Food Standards Code, with strict requirements for substantiation.

Japan: In Japan, L. plantarum can be used in Foods for Specified Health Uses (FOSHU) if approved by the Consumer Affairs Agency. It is also permitted in regular foods and as an ingredient in ‘Foods with Function Claims’ (FFC) if scientific evidence supports the claimed benefits. Japan has a long history of accepting probiotic foods, with fermented products containing L. plantarum widely available. Several L. plantarum products have received FOSHU approval for specific health claims.

China: In China, L. plantarum is included in the list of approved probiotic strains for use in foods by the National Health Commission. For use in health foods (similar to dietary supplements), approval from the State Administration for Market Regulation (SAMR) is required. The regulatory framework for probiotics in China has been evolving, with increasing scrutiny of health claims. L. plantarum is widely used in traditional fermented foods in China, which have their own regulatory frameworks.

India: The Food Safety and Standards Authority of India (FSSAI) permits L. plantarum in certain food categories, including fermented foods and dairy products. For use in nutraceuticals or health supplements, it must comply with the Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food) Regulations.

The regulatory landscape for L. plantarum and other probiotics faces several challenges. There is significant international variation in how probiotics are regulated, creating complexity for global marketing. Strain-specific effects are not always reflected in regulatory frameworks, which may treat all L.

plantarum strains as equivalent despite evidence of strain-specific benefits (particularly for strains like 299v). Dosage standardization is lacking, with no consensus on minimum effective doses for different health applications. Quality control standards vary widely, with inconsistent requirements for viability testing, contamination screening, and stability assessment. Health claim substantiation requirements differ significantly between jurisdictions, with some regions (like the EU) having very stringent requirements that few probiotic products can meet.

The line between food and supplement/drug classifications is often blurry for probiotic products, creating regulatory uncertainty. This is particularly relevant for L. plantarum, which has a dual identity as both a traditional food component and a modern supplement ingredient. Emerging delivery formats (e.g., probiotic-infused beauty products, lozenges, or topical applications) may fall into regulatory gray areas.

Safety monitoring systems for probiotics are less developed than for conventional drugs, though adverse events appear to be rare in healthy populations. As research advances on the microbiome and probiotic mechanisms, regulatory frameworks may need to evolve to accommodate new understanding and applications. The recent taxonomic reclassification of L. plantarum to Lactiplantibacillus plantarum may create additional regulatory complexities during the transition period as labels and regulatory documents are updated.

medium

The cost of Lactobacillus plantarum supplements varies widely based on formulation, strain specificity (particularly whether it contains well-researched strains like 299v), CFU count, and additional ingredients. Basic L. plantarum supplements typically range from $0.10 to $0.50 per billion CFU. For a typical effective dose of 1-10 billion CFU daily for general health maintenance, this translates to approximately $0.10-$5.00 per day.

Higher potency supplements (10-20 billion CFU) generally cost $0.30-$1.50 per day. Premium formulations with verified specific strains like L. plantarum 299v, advanced delivery systems, or additional ingredients can cost $1.00-$3.00 per day. Specialized therapeutic formulations for specific conditions may cost up to $3.00-$5.00 per day.

Food sources of L. plantarum, such as fermented vegetables (sauerkraut, kimchi) or sourdough bread, typically cost $0.50-$3.00 per serving, though CFU counts are often not standardized or verified in these foods. Homemade fermented foods containing L. plantarum can be extremely cost-effective, with ingredients costing as little as $0.10-$0.30 per serving, though preparation requires time and knowledge.

The cost-effectiveness of L. plantarum supplementation varies by application and individual needs. For irritable bowel syndrome (IBS), L. plantarum 299v supplementation offers good value, with clinical studies showing significant symptom improvement at doses costing approximately $1.00-$2.00 per day.

Compared to prescription medications for IBS, which can cost $5-$15 per day and often have more side effects, L. plantarum represents a cost-effective option, particularly for mild to moderate cases. For general digestive health maintenance in healthy individuals, the value proposition is less clearly established. Lower-cost options ($0.10-$0.30 per day) may be reasonable for preventive health, while premium products may not offer proportionally greater benefits for general wellness.

For intestinal barrier function improvement (‘leaky gut’), L. plantarum shows promising value, as it has demonstrated specific effects on tight junction proteins at doses costing approximately $0.50-$1.50 per day. This may represent good value compared to multiple supplements often used for this purpose. For antibiotic-associated diarrhea prevention, L.

plantarum supplementation is generally cost-effective, as the cost of supplementation ($10-$30 for a typical antibiotic course) is substantially lower than potential costs associated with treating diarrhea, including medication, lost productivity, and in severe cases, hospitalization. Food sources of L. plantarum (fermented vegetables, sourdough bread) often provide excellent value for general health maintenance, combining nutritional benefits with probiotic delivery, though at less standardized doses. Homemade fermented foods containing L.

plantarum represent perhaps the best value, though they require time and knowledge to prepare properly. Generic or store-brand probiotic supplements can offer good value, but verification of strain identity is important, particularly when seeking well-researched strains like 299v. Multi-strain formulations typically cost more but may provide broader benefits than single-strain L. plantarum products.

The most cost-effective approach often involves targeted, time-limited use for specific conditions rather than indefinite daily supplementation without a clear indication. For individuals with chronic digestive issues who respond well to L. plantarum, however, ongoing supplementation may represent good value compared to alternative treatments or the impact of untreated symptoms on quality of life.

The shelf life of Lactobacillus plantarum products varies significantly based on formulation, packaging, and storage conditions. Properly manufactured and stored freeze-dried L. plantarum supplements typically maintain acceptable viability for 18-24 months from the date of manufacture. L.

plantarum has demonstrated relatively good stability compared to many other probiotic strains, with some properly formulated products maintaining viability for up to 24-36 months at room temperature. This enhanced stability is partly due to L. plantarum’s natural resistance to environmental stressors. Refrigerated liquid formulations generally have a shorter shelf life of 2-3 months.

Microencapsulated or specially formulated shelf-stable products may maintain viability for up to 24-36 months at room temperature. Probiotic-fortified foods containing L. plantarum, such as fermented vegetables, can maintain viable counts for several months under proper refrigeration. Traditional fermented foods like properly prepared sauerkraut or kimchi can maintain viable L.

plantarum for 6-12 months under appropriate storage conditions.

Refrigeration (36-46°F/2-8°C) is optimal for most L. plantarum supplements, even those labeled as shelf-stable, as it significantly extends viability. If refrigeration is not possible, store in a cool, dry place away from direct sunlight, heat sources, and humidity. Temperature fluctuations should be minimized, as repeated warming and cooling can reduce viability.

Keep containers tightly closed when not in use to prevent moisture exposure. For blister-packed probiotics, only remove capsules/tablets when ready to consume. Liquid formulations almost always require refrigeration after opening. Follow manufacturer-specific storage instructions, as some advanced formulations may have different requirements.

When traveling, consider using insulated containers with ice packs for temperature-sensitive formulations, or look for specially designed shelf-stable travel formulations. L. plantarum has demonstrated relatively good stability at room temperature compared to many other probiotic strains, but refrigeration will still extend its shelf life. For fermented foods containing L.

plantarum, follow specific storage guidelines for that food; most require refrigeration after opening.

Heat: Temperatures above 77°F/25°C accelerate die-off of live bacteria; exposure to temperatures above 104°F/40°C can cause rapid loss of viability. L. plantarum has somewhat better heat resistance than some other probiotic species but is still sensitive to high temperatures., Moisture: Exposure to humidity or moisture activates freeze-dried bacteria prematurely, depleting their energy reserves and reducing shelf life., Oxygen: L. plantarum is microaerophilic (prefers low oxygen), and excessive oxygen exposure can reduce viability through oxidative damage, though it is more oxygen-tolerant than some strictly anaerobic probiotics., Light: Direct sunlight and UV light can damage bacterial cells through photodegradation and generation of reactive oxygen species., pH extremes: While L. plantarum is relatively acid-tolerant compared to many probiotics, extreme pH conditions during storage can still reduce viability., Freeze-thaw cycles: Repeated freezing and thawing creates ice crystals that can damage bacterial cell walls., Chemical preservatives: Many preservatives used in foods and supplements are designed to inhibit microbial growth and may affect probiotic viability., Compression and processing: Mechanical stress during manufacturing and compression into tablets can damage bacterial cells., Interaction with other ingredients: Certain active ingredients in multi-component supplements may have antimicrobial properties that reduce probiotic viability over time.

Several technologies have been developed to enhance the stability of L. plantarum products. Microencapsulation protects bacteria with a protective coating that shields them from environmental stressors and controls their release. Freeze-drying (lyophilization) removes water while preserving the cellular structure, significantly extending shelf life.

Addition of cryoprotectants like trehalose, sucrose, or glycerol helps protect bacterial cells during freeze-drying and storage. Specialized packaging such as nitrogen-flushed bottles, blister packs, or aluminum foil sachets reduces exposure to oxygen and moisture. Some formulations include prebiotics that not only support growth in the gut but may also enhance stability during storage. Advanced formulations may incorporate acid-resistant strains (L.

plantarum is naturally relatively acid-resistant) or add buffering agents to protect against pH fluctuations. Vacuum-sealed packaging removes oxygen that could damage sensitive probiotic strains. Cold-chain management throughout manufacturing, distribution, and retail ensures optimal temperature conditions are maintained. Some manufacturers use overages (adding more CFUs than stated on the label) to compensate for expected die-off during shelf life, ensuring that the product contains at least the labeled amount of viable probiotics through the expiration date.

Recent innovations include the use of plant-based matrices that naturally enhance L. plantarum stability, mimicking its natural habitat on plant surfaces.

Synthesis Methods

Natural Sources

Quality Considerations

Lactobacillus plantarum has one of the longest histories of human use among probiotic species, as it is a dominant microorganism in many traditional fermented foods consumed across diverse cultures for thousands of years. While the bacterium itself wasn’t identified until modern times, its effects have been utilized throughout human history. L. plantarum is naturally present in many plant-based fermented foods, including sauerkraut, kimchi, pickled vegetables, olives, and sourdough bread, which have been staples in various cultures for millennia.

The fermentation of vegetables for preservation is one of the oldest food processing techniques, dating back to at least 6000 BCE in the Middle East and likely earlier in other regions. These fermentation practices, which naturally cultivate L. plantarum, spread throughout Europe, Asia, and eventually worldwide. In East Asia, kimchi and other fermented vegetables containing L.

plantarum have been consumed for over 2,000 years. In Eastern Europe, sauerkraut production dates back to at least the 16th century, though similar fermented cabbage preparations were likely made much earlier. Traditional olive fermentation in Mediterranean cultures, which relies heavily on L. plantarum, has been practiced for thousands of years.

Sourdough bread, which often contains L. plantarum as part of its microbial community, has been made since ancient Egyptian times. The scientific identification and study of L. plantarum began in the early 20th century.

The species was first isolated and described in 1919 by Orla-Jensen from dairy products, though it was initially classified under different taxonomic designations before being recognized as a distinct species. The name ‘plantarum’ refers to its common occurrence on plant material. Throughout the mid-20th century, microbiologists began to understand the role of L. plantarum in various fermentation processes, particularly in vegetable fermentations.

Its ability to produce lactic acid and antimicrobial compounds was recognized as crucial for food preservation and safety. The modern scientific interest in L. plantarum as a probiotic began in the 1980s and 1990s, with early research focusing on its potential to survive gastrointestinal transit and colonize the human gut. A significant milestone came in the 1990s with the isolation and characterization of specific strains like L.

plantarum 299v from human intestinal mucosa by researchers at Lund University in Sweden. This strain would go on to become one of the most studied probiotic strains worldwide. In 1999, L. plantarum became one of the first probiotic bacteria to have its complete genome sequenced (strain WCFS1), which greatly accelerated research into its mechanisms of action and potential health benefits.

The early 2000s saw a surge in clinical research on L. plantarum, with studies investigating its effects on conditions ranging from irritable bowel syndrome to immune function. The 299v strain, in particular, gained significant scientific support for its benefits in IBS. In recent decades, L.

plantarum has become one of the most widely used probiotics in both food products and supplements, with applications ranging from general digestive health to specific clinical conditions. In 2020, taxonomic revisions led to the reclassification of many Lactobacillus species into new genera, with L. plantarum being reclassified as Lactiplantibacillus plantarum. However, the name Lactobacillus plantarum remains in common use in both scientific and commercial contexts.

Today, L. plantarum is recognized not only for its historical role in food fermentation but also as a scientifically validated probiotic with specific health benefits, representing a bridge between traditional food practices and modern evidence-based supplementation.

Ford AC, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: Systematic review and meta-analysis. Am J Gastroenterol. 2014;109(10):1547-1561., Hungin APS, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms – an updated evidence-based international consensus. Aliment Pharmacol Ther. 2018;47(8):1054-1070., Lau CSM, et al. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med. 2016;9:27-37., Shen J, et al. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn’s disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis. 2014;20(1):21-35., Guo Q, et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2019;4:CD004827.

Lactobacillus plantarum for Prevention of Necrotizing Enterocolitis in Very Low Birth Weight Infants (ClinicalTrials.gov Identifier: NCT03941782), Efficacy of Lactobacillus plantarum in Children with Autism Spectrum Disorder (ClinicalTrials.gov Identifier: NCT04073927), Lactobacillus plantarum for Management of Irritable Bowel Syndrome in Adults (ClinicalTrials.gov Identifier: NCT04125563), Effects of Lactobacillus plantarum on Cognitive Function in Older Adults (ClinicalTrials.gov Identifier: NCT04153214), Lactobacillus plantarum as an Adjunct to Standard Therapy for Helicobacter pylori Eradication (ClinicalTrials.gov Identifier: NCT03902561)

Lactobacillus plantarum has a substantial body of scientific evidence supporting several of its health benefits, with the strongest evidence for specific strains like L. plantarum 299v. The most robust evidence supports the use of L. plantarum for irritable bowel syndrome (IBS), with multiple randomized controlled trials showing significant improvements in symptoms, particularly abdominal pain and bloating.

The 299v strain has the most extensive clinical research for this application. There is strong mechanistic evidence for L. plantarum’s ability to strengthen intestinal barrier function, with both in vitro and in vivo studies demonstrating its effects on tight junction proteins and reduction of intestinal permeability. This mechanism is particularly relevant for conditions associated with increased intestinal permeability, such as inflammatory bowel disease and alcohol-related liver disease.

Moderate evidence supports the use of L. plantarum for preventing antibiotic-associated diarrhea and Clostridium difficile infection, with several clinical trials showing positive results, particularly in hospital settings. The evidence for L. plantarum in inflammatory bowel disease (IBD) is promising but less consistent, with some studies showing benefits as an adjunct to conventional therapy, particularly for maintaining remission in ulcerative colitis.

Emerging evidence suggests potential benefits of L. plantarum for metabolic parameters, including glycemic control and lipid profiles, though more research is needed in this area. There is also growing interest in L. plantarum’s effects on the gut-brain axis, with preliminary studies exploring its potential benefits for cognitive function, mood, and stress-related disorders.

The quality of evidence varies across different applications, with the strongest evidence coming from multiple well-designed randomized controlled trials for IBS and intestinal barrier function. For other applications, the evidence may be limited by smaller sample sizes, heterogeneity in study designs, or inconsistent results across studies. It’s important to note that the effects of L. plantarum are strain-specific, with strains like 299v, WCFS1, and MB452 having the most extensive research support.

Other strains may have different effects and levels of evidence. Future research directions include larger, longer-term clinical trials, studies on specific mechanisms of action, exploration of strain-specific effects, and investigation of potential applications in neurological and metabolic disorders.